Drug Trial Radar · NCT04985942
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
485
Actual
Start
Jul 30, 2021
Primary completion
Feb 22, 2024
Study completion Feb 27, 2024
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Conditions
- Major Depressive Disorder
Interventions
LumateperoneDrug
Lumateperone 42 mg capsules administered orally, once daily.
PlaceboDrug
Matching capsules administered orally, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Montgomery-Åsberg Depression Rating ScaleTime frame: Day 43
Locations
54 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Site
Phoenix, Arizona
Clinical Site
Glendale, California
Clinical Site
Oceanside, California
Clinical Site
Redlands, California
Clinical Site
Temecula, California
Clinical Site
Upland, California
Clinical Site
Fort Lauderdale, Florida
Clinical Site
Jacksonville, Florida
Clinical Site
Orlando, Florida
Clinical Site
Decatur, Georgia
Clinical Site
Boston, Massachusetts
Clinical Site
Berlin, New Jersey
Clinical Site
Toms River, New Jersey
Clinical Site
Cedarhurst, New York
Clinical Site
Austin, Texas
Clinical Site
Burgas, Bulgaria
Clinical Site
Kazanlak, Bulgaria
Clinical Site
Pleven, Bulgaria
Clinical Site
Rousse, Bulgaria
Clinical Site
Tsarev Brod, Bulgaria
Clinical Site
Veliko Tarnovo, Bulgaria
Clinical Site
Veliko Tarnovo, Bulgaria
Clinical Site
Vratsa, Bulgaria
Clinical Site
Brno, Czechia
Clinical Site
Brno, Czechia
Clinical Site
Ostrava, Czechia
Clinical site
Pilsen, Czechia
Clinical Site
Prague, Czechia
Clinical Site
Prague, Czechia
Clinical Site
Budapest, Hungary
Clinical Site
Budapest, Hungary
Clinical Site
Budapest, Hungary
Clinical Site
Gyöngyös, Hungary
Clinical Site
Guwahati, Assam, India
Clinical Site
Ahmedabad, Gujarat, India
Clinical Site
Jūnāgadh, Gujarat, India
Clinical Site
Vadodara, Gujarat, India
Clinical Site
Mangaluru, Karnataka, India
Clinical Site
Mysore, Karnataka, India
Clinical Site
Kozhikode, Kerala, India
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.